We are live on ! Find out more
FENC icon

Fennec Pharmaceuticals
FENC

49 hedge funds and large institutions have $46.7M invested in Fennec Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 17 increasing their positions, 11 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 2

55% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 11

4% more funds holding

Funds holding: 47 → 49 (+2)

0.94% less ownership

Funds ownership: 49.38% → 48.44% (-0.94%)

25% less capital invested

Capital invested by funds: $62.2M → $46.7M (-$15.4M)

Holders
49
Holders Change
+2
Holders Change %
+4.26%
% of All Funds
1.06%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
17
Reduced
11
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
OAM
Oxford Asset Management
United Kingdom
+$463K
2
GIM
Granahan Investment Management
Massachusetts
+$302K
3
Renaissance Technologies
Renaissance Technologies
New York
+$204K
4
Deutsche Bank
Deutsche Bank
Germany
+$204K
5
USAA
United Services Automobile Association
Texas
+$131K

Top Sellers

Rank Fund Capital Flow
1
OM
Opaleye Management
Massachusetts
-$1.78M
2
Russell Investments Group
Russell Investments Group
United Kingdom
-$178K
3
BlackRock
BlackRock
New York
-$148K
4
Morgan Stanley
Morgan Stanley
New York
-$123K
5
UBS Group
UBS Group
Switzerland
-$45.3K
Name Holding Trade Value Shares
Change 		Change in
Stake
SCA
1
Southpoint Capital Advisors
New York
$19.4M – – –
ACA
2
Avoro Capital Advisors
New York
$5.36M – – –
6CM
3
683 Capital Management
New York
$4.71M – – –
EAM
4
Eventide Asset Management
Massachusetts
$3.49M – – –
OM
5
Opaleye Management
Massachusetts
$3.06M -$1.78M -270,000 -30%
BlackRock
6
BlackRock
New York
$2.62M -$148K -22,437 -4%
GIM
7
Granahan Investment Management
Massachusetts
$1.99M +$302K +45,999 +13%
PI
8
Putnam Investments
Massachusetts
$1.27M – – –
USAA
9
United Services Automobile Association
Texas
$844K +$131K +19,860 +13%
State Street
10
State Street
Massachusetts
$812K +$35.9K +5,454 +3%
Northern Trust
11
Northern Trust
Illinois
$495K +$1.45K +220 +0.2%
OAM
12
Oxford Asset Management
United Kingdom
$411K +$463K +70,391 +490%
Geode Capital Management
13
Geode Capital Management
Massachusetts
$223K +$43.2K +6,570 +17%
Deutsche Bank
14
Deutsche Bank
Germany
$222K +$204K +31,073 +206%
Vanguard Group
15
Vanguard Group
Pennsylvania
$219K +$22.7K +3,458 +8%
PPA
16
Parametric Portfolio Associates
Washington
$205K +$69.3K +10,538 +33%
Renaissance Technologies
17
Renaissance Technologies
New York
$151K +$204K +31,100 New
Charles Schwab
18
Charles Schwab
California
$132K +$40.2K +6,111 +29%
WMSA
19
Weiss Multi-Strategy Advisers
New York
$121K – – –
Bank of New York Mellon
20
Bank of New York Mellon
New York
$111K – – –
California State Teachers Retirement System (CalSTRS)
21
California State Teachers Retirement System (CalSTRS)
California
$91K – – –
ZCM
22
Zebra Capital Management
Connecticut
$85K – – –
State of Wisconsin Investment Board
23
State of Wisconsin Investment Board
Wisconsin
$76K +$23.7K +3,600 +30%
Wells Fargo
24
Wells Fargo
California
$75K -$112 -17 -0.1%
TA
25
Teachers Advisors
New York
$74K – – –
1
2

FENC Hedge Fund Activity: Q1 2019 in Review

49 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Fennec Pharmaceuticals (FENC) for Q1 2019, worth a combined $46.7M — down 25% from $62.2M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new FENC positions and 2 closed out — a net gain of 2 holders — while 17 added to existing stakes and 11 trimmed.

The largest buyer was Oxford Asset Management, adding an estimated $463K. The largest seller was Opaleye Management, cutting an estimated $1.78M.

  • 49 institutional investors held Fennec Pharmaceuticals (FENC) as of Q1 2019, up from 47 in Q4 2018.
  • Funds reported $46.7M of Fennec Pharmaceuticals stock for Q1 2019, down 25% quarter-over-quarter.
  • 4 funds opened new Fennec Pharmaceuticals positions in Q1 2019 and 2 closed out, a net change of +2 holders.
  • The largest Fennec Pharmaceuticals buyer in Q1 2019 was Oxford Asset Management, an estimated $463K added.
  • The largest Fennec Pharmaceuticals seller in Q1 2019 was Opaleye Management, an estimated $1.78M sold.

Based on aggregated 13F filings for Q1 2019.